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ABSTRACT
CCT245737 is the first orally active, clinical development candidate CHK1 inhibitor 
to be described. The IC50 was 1.4nM against CHK1 enzyme and it exhibited>1,000-
fold selectivity against CHK2 and CDK1. CCT245737 potently inhibited cellular CHK1 
activity (IC50 30-220nM) and enhanced gemcitabine and SN38 cytotoxicity in multiple 
human tumor cell lines and human tumor xenograft models. Mouse oral bioavailability 
was complete (100%) with extensive tumor exposure. Genotoxic-induced CHK1 
activity (pS296 CHK1) and cell cycle arrest (pY15 CDK1) were inhibited both in vitro 
and in human tumor xenografts by CCT245737, causing increased DNA damage and 
apoptosis. Uniquely, we show CCT245737 enhanced gemcitabine antitumor activity 
to a greater degree than for higher doses of either agent alone, without increasing 
toxicity, indicating a true therapeutic advantage for this combination. Furthermore, 
development of a novel ELISA assay for pS296 CHK1 autophosphorylation, allowed 
the quantitative measurement of target inhibition in a RAS mutant human tumor 
xenograft of NSCLC at efficacious doses of CCT245737. Finally, CCT245737 also 
showed significant single-agent activity against a MYC-driven mouse model of B-cell 
lymphoma. In conclusion, CCT245737 is a new CHK1 inhibitor clinical development 
candidate scheduled for a first in man Phase I clinical trial, that will use the novel 
pS296 CHK1 ELISA to monitor target inhibition.
INTRODUCTION
The DNA damage response (DDR) pathway has 
evolved to protect cells from genetic insults in an effort 
to preserve genomic integrity and cell viability [1, 2]. 
Anticancer chemotherapy often includes DNA damaging 
agents which activate the DDR [3]. An important gene 
in this process is TP53 which can induce G1/S cell cycle 
arrest and either DNA repair or apoptosis [4]. A hallmark 
of many tumors is the lack of functional p53 protein 
with a consequent loss of the G1/S checkpoint leading 
to a potential increase in reliance on the S and G2/M 
checkpoints for survival following genotoxic stress [5]. 
This has therefore stimulated the development of selective 
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G2 checkpoint inhibitors for combination with DNA 
damaging anticancer drugs [6-9] .
One potential drug target controlling this checkpoint 
is the serine/threonine kinase CHK1 which has been shown 
to be involved in the G1 and G2 checkpoints through 
altering CDC25A stability and CDC25C localization, 
respectively [3, 10, 11]. CHK1 also maintains replication 
fork stability (and hence the S-phase checkpoint) and has 
been implicated in facilitating homologous recombination 
repair [10, 12, 13]. As a result of promising early studies, 
several CHK1 inhibitors have been developed and are 
currently undergoing clinical evaluation in combination 
with genotoxic drugs [6, 8, 14-16].
Recent studies have also indicated that CHK1 
inhibition alone may have therapeutic activity in certain 
genetic backgrounds [6, 17, 18]. There is increasing 
evidence that many tumors harbor substantial amounts 
of DNA damage as a result of replication stress. This 
process appears to be intimately associated with tumor 
development and may arise as a result of oncogene-
induced increases in the firing of replication origins. As 
a consequence, depletion of RPA and dNTPs results in 
the accumulation of stalled replication forks [19, 20]. 
This in turn leads to an increased requirement for CHK1 
to prevent fork collapse and DNA damage. In support of 
this hypothesis, single-agent CHK1 inhibitor activity has 
been demonstrated in several tumor types including MYC-
driven tumors such as neuroblastoma and lymphoma 
as well as acute myeloid leukemia and melanoma, all 
diseases thought to be associated with high levels of 
replication stress [17, 18, 21, 22] . 
We have therefore discovered a novel, potent, 
orally active CHK1 inhibitor and clinical development 
candidate: CCT245737. Here we describe the preclinical 
pharmacology and pharmacodynamics (PD) of this 
compound together with its therapeutic activity in 
combination with various genotoxic anticancer drugs in 
multiple human tumor xenografts. Uniquely, we present 
clear evidence that the combination of gemcitabine and 
CCT245737 provides a substantial therapeutic advantage 
over either agent alone in an antitumor context, thus 
validating this approach. We describe a novel ELISA 
for pS296CHK1, which demonstrated target inhibition 
following CCT245737 treatment at efficacious doses with 
gemcitabine and carboplatin in a RAS mutant human 
tumor xenograft model of NSCLC, an area of unmet 
clinical need in cancer treatment. In addition CCT245737 
showed significant antitumor activity as a single-agent 
in an Eµ-Myc driven mouse model of B-cell lymphoma. 
Consequently CCT245737 is in late stage preclinical 
development for scheduled entry into phase I clinical 
trials.
RESULTS
Structure and kinase selectivity of CCT245737
Figure 1A shows the chemical structure of 
CCT245737 ((R)-5-((4-((morpholin-2-ylmethyl)amino)-
5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-
carbonitrile). A model of CCT245737 bound in the ATP 
pocket of human CHK1 is shown in Supplementary 
Figure S1 and suggests that key interactions in the ATP 
binding site have been retained through hydrogen bonding 
to Glu85 and Cys87 in the hinge region, the hydrogen 
bonding of the nitrile to Lys38, while the basic nitrogen 
on the morpholine forms a salt bridge to Glu91. Similar 
binding poses have been observed for several other 
2-amino-pyrazine-5-carbonitrile CHK1 inhibitors [23].
Initial in vitro kinase profiling of CCT245737 
(10µM) against 124 kinases showed that only 12 kinases 
(including CHK1) had > 80% inhibition (Supplementary 
Table 1). In vitro IC50 values were determined for these 
12 kinases and five others including CDK2/CycA and 
CDK1/CycB (Supplementary Table 2). CCT245737 
was a potent inhibitor of recombinant human CHK1 
with IC50 of 1.4±0.3nM (mean±SD, n = 3, EZ Reader 
II assay). There was > 1,000-fold selectivity for CHK1 
versus the functionally important kinases CDK1 and 
CHK2 (IC50 1.26-2.44 and 9.03 µM, respectively), and at 
least a 90-fold selectivity against cross-reacting kinases 
such as ERK8, PKD1, RSK1 and 2 (see Supplementary 
Table 2, 33P radiometric assay); thus demonstrating that 
CCT245737 is a potent and selective CHK1 inhibitor. 
Cellular pharmacology of CCT245737
The ability of CCT245737 to abrogate an etoposide-
induced G2 checkpoint (MIA) in four cell lines is shown 
in Table 1 and IC50 values ranged from 30 to 220nM, 
confirming potent cellular CHK1 inhibition. There was 
a greater than 10-fold range in GI50 (0.41 to 5.4µM) for 
single-agent CCT245737 in these cell lines. Cell cycle 
studies (Figure 1B) showed that CCT245737 had minimal 
effects in HT29 cells up to 0.5µM for 24h, but at higher 
concentrations there was an apparent decrease in the 
G1/Go population and a concomitant increase in the S’ 
population, which are unlabelled S-phase cells that may 
represent a replication crisis [24]. Etoposide alone caused 
a marked loss of G1/G0 and a corresponding G2/M block. 
The addition of increasing concentrations of CCT245737 
abrogated this G2/M block with a corresponding increase 
in the S’-phase population, confirming that CCT245737 
can abrogate an etoposide-induced G2/M arrest. 
Previous studies have established that the 
antimetabolite gemcitabine and topoisomerase 1 inhibitor 
SN38 are amongst the best candidate drugs for combination 
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with CHK1 inhibitors [24, 25]. Table 1 confirms that in 
several human tumor cell lines, CCT245737 significantly 
enhanced the cytotoxicity of these two anticancer drugs 
with the greatest potentiation occurring with gemcitabine 
(Figure 1C). Importantly, similar studies using a more 
conventional approach to determining the potentiation, 
with minimally toxic concentrations of CCT245737 
and a range of genotoxic drug concentrations, showed a 
similar relationship (Supplementary Figure 2). However, 
this conventional assay showed less potentiation and 
was markedly more sensitive to variations in the CHK1 
inhibitor concentration employed, which has implications 
for early drug development as discussed later. There was 
no statistically significant difference in cytotoxicity, MIA 
or PI activity of the S-enantiomer CCT252463 compared 
with CCT245737 (data not shown).
Cellular PD biomarker studies in HT29 colon 
tumor cells showed that gemcitabine markedly 
induced autophosphorylation of CHK1 on S296 and 
phosphorylation of S280, S317 and S345 (Figure 1D). 
In addition, pY15 CDK1 was increased, consistent 
with a drug-induced cell cycle arrest. The addition of 
≥0.5µM CCT245737 to gemcitabine caused a marked 
loss of pS296 signal with complete inhibition at ≥2µM 
CCT245737. Similar effects were seen on pS317 CHK1 
but by contrast there was less marked or minimal 
inhibition of the other CHK1 phosphorylation sites (pS280 
and pS345) or alteration in the expression of total CHK1. 
Loss of pY15 CDK1 corresponded exactly with loss of 
pS296 CHK1, consistent with abrogation of cell cycle 
Figure 1: Structure and cellular pharmacology of CCT245737. A. Chemical structure of CCT245737 B. Effects of 24h exposure 
to CCT245737 either alone or following acute etoposide exposure (50µM x 1h) on the cell cycle distribution in HT29 colon carcinoma 
cells. BrdU and PI staining were carried out as described in Materials and Methods. Similar results were obtained in a repeat experiment. 
C. Representative results for a potentiation assay using a fixed concentration of gemcitabine (GI50, ▲ ) and increasing concentrations of 
CCT245737 either alone ( ◊ ) or in combination with gemcitabine (●) in SW620 colon cancer cells. Vehicle treated cells ( ∆ ). Data points 
are mean±SE for 4 replicates. D. Characterization of the effects of CCT245737 on gemcitabine-induced biomarker expression in HT29 
colon cancer cells. Protein expression was measured using western blotting as described in Materials and Methods with 50μg sample per 
lane. GAPDH was used as a loading control. Similar results were obtained in a repeat experiment. 
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checkpoint and there was a marked co-ordinate increase 
in pS139 H2AX (γH2AX) a marker of DNA double-
strand breaks and cleaved PARP, a marker of apoptosis. 
Loss of other inhibitory phosphorylations, such as pT14 
CDK1 might further enhance the activity of CCT245737. 
These observations imply that CCT245737 caused CHK1 
inhibition, abrogated gemcitabine induced cell cycle arrest 
causing DNA damage and cell death. Similar results were 
obtained in the SW620 colon cancer cell line with either 
gemcitabine or SN38 (Supplementary Figure 3). These 
data confirm that CCT245737 can inhibit CHK1 activity 
and enhance the cytotoxicity of gemcitabine and SN38 in 
several human cancer cells line in vitro.
Pharmacokinetic and pharmacodynamic 
relationships of CCT245737 in human tumor 
xenografts in mice
A critical step in successful drug development is 
characterization of the pharmacokinetics and metabolism 
of a molecule, to ensure effective tissue drug exposure 
[26, 27]. Figure 2A and Supplementary Table 3 summarize 
the pharmacokinetics of CCT245737 in BALB/c mice 
following either i.v. or p.o. administration. An i.v. dose of 
10mg/kg CCT245737 gave a peak plasma concentration 
of 4µmol/L, with a half-life of 2.86h, an AUC
0-∞
 of 
9.96µmol.h/L, a plasma clearance of 2.1L/h/kg and a 
large volume of distribution (0.19L). The equivalent oral 
dose gave an almost identical profile with an AUC
0-∞
 of 
Figure 2: Summary of the pharmacokinetic and pharmacodynamic properties of CCT245737 in vivo. A. Pharmacokinetics 
of CCT245737 in plasma and spleen following single bolus administration of 10mg/kg either i.v. or p.o. in BALB/c mice. B. Relationship 
between drug exposure (blood AUC) and drug dose for CCT245737 in BALB/c mice. C. Pharmacodynamic effects of CCT245737 on 
gemcitabine-induced CHK1 and cell cycle biomarkers at 24h in human HT29 colon carcinoma xenografts. A single dose of gemcitabine 
was administered on day 0 (100mg/kg i.v.) and a single dose of CCT245737 administered 24h later (50 or 100mg/kg p.o.) and samples were 
taken 24h following the last drug dose. Protein expression was measured by western blotting as described in Materials and Methods and 
GAPDH was used as a loading control. Similar results were obtained at the 6h time point. D. Quantification of the pharmacodynamic effects 
of CCT245737 shown in Figure 2C. Protein expression was quantified using ImageQuant software and normalized to GAPDH expression. 
Values are mean±SE, n = 3 and statistical analysis was by one-way ANOVA with Dunnett’s correction; *P < 0.05 indicates a significant 
difference from gemcitabine treatment alone. 
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10.4µmol.h/L showing complete oral bioavailability (F = 
105%). Plasma protein binding in nude mice was 75.6% 
at 10µM CCT245737. In addition, this compound has 
high cell permeability, as measured by transport across a 
CaCo2 cell monolayer, with Pe = 25x10-6cm/s. Moreover, 
there was no evidence of asymmetry in the permeability 
with apical > basal or basal > apical across the monolayer, 
indicating that the compound is not a substrate for active 
efflux by PGP. CCT245737 had linear kinetics in whole 
blood (Figure 2B). Consistent with the large volume of 
distribution, concentrations of CCT245737 in the spleen 
were 10 to 25 times greater than in the plasma for both 
routes of administration and this was reflected in the 
correspondingly greater AUC
0-∞
 (Supplementary Table 
3). Similarly high tumor/plasma ratios were obtained in 
HT29 xenografts treated with a fixed dose of gemcitabine 
and different doses of CCT245737 (Supplementary 
Figure 4). Moreover, 24h following a dose of 12.5mg/kg 
Figure 3: Therapeutic activity of CCT245737 in combination with gemcitabine or irinotecan in human tumor 
xenografts. A. CCT245737 enhances the antitumor effects of gemcitabine in HT29 human colon cancer xenografts. Symbols and 
treatments: o vehicle; ∆ gemcitabine alone (100mg/kg i.v. days 0,7 and 14); ▲ CCT245737 alone (150mg/kg p.o. days 1,2; 8,9 and 15,16) 
and ● combination of gemcitabine + CCT245737 at doses and schedules shown for single agents. Values are mean±SE with 5-6 mice per 
point. B. Summary of the antitumor effects of different oral doses of CCT245737 combined with a fixed dose of gemcitabine (100mg/kg 
i.v.) in HT29 human colon carcinoma xenografts. The activity of the MTD for single dose gemcitabine (200mg/kg i.v.) and CCT245737 
(150mg/kg p.o.) are also shown (dashed line). Growth delays (days) were determined in several independent experiments and are shown as 
mean±SE for n = 6-10 mice per point. C. Antitumor efficacy of irinotecan or CCT245737 alone or in combination in HT29 human colon 
carcinoma xenografts. Symbols and treatments: o vehicle; ∆ irinotecan alone (25mg/kg i.p. days 0,4 and 8); ▲ CCT245737 alone (150mg/
kg p.o. days 1,2; 5,6; 9 and 10) and ● gemcitabine + CCT245737 combination at times and doses shown for single agents. D. Antitumor 
activity of gemcitabine or CCT245737 alone or combined in SW620 human colon cancer xenografts. Symbols and treatments: o vehicle; 
∆ gemcitabine alone (100mg/kg i.v. days 0,4 and 8); ▲ CCT245737 alone (150mg/kg p.o. days 1,2; 5,6; 9 and 10) and ● gemcitabine + 
CCT245737 combination at times and doses shown for single agents. Values are mean±SE, n = 5-10 mice per point for C. and D.. Tumor 
size and growth delay were determined as described in Materials and Methods. The black arrows in A., C. and D. indicate when the 
genotoxic agent was administered and the open arrow heads represent CCT245737 administration with day 0 being the start of therapy of 
established tumors.
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p.o. CCT245737, mean tumor drug concentrations were 
≥ 3µmol/L, a value that would be expected to markedly 
inhibit cellular CHK1 kinase activity (see MIA IC50 Table 
1) and gave significant antitumor activity (Supplementary 
Table 4). 
An in vivo pharmacokinetic-pharmacodynamic (PK-
PD) study in HT29 tumor xenografts taken from mice 
administered gemcitabine followed by CCT245737 is 
shown in Figure 2C and 2D. Gemcitabine alone (100mg/
kg i.v.) caused marked pS296 CHK1 induction along 
with pS317 CHK1 and pY15 CDK1. The addition of 
CCT245737 at 50 or 100mg/kg p.o. significantly reduced 
the pS296 signal and pY15 CDK1 at the higher dose (P 
< 0.05, Figure 2D) but not pS317, consistent with CHK1 
inhibition in vivo and the in vitro cellular data (see Figure 
1D, Supplementary Figure 3). These PK-PD studies show 
that following oral administration, for a range of drug 
doses, adequate CCT245737 tumor drug exposure for 
durable CHK1 inhibition can be achieved. 
Therapeutic activity of CCT245737 combinations 
in human tumor xenografts
Extensive antitumor studies were carried out using 
gemcitabine and different doses of CCT245737 in HT29 
human colon tumor xenografts (Figure 3A, 3B and 
Supplementary Table 4). Figure 3A shows that CCT245737 
(150mg/kg p.o.) or gemcitabine alone (100mg/kg i.v.) had 
minimal antitumor activity with growth delays of 0.3±3.4 
and -0.6±2.7 days, respectively (mean±SD, Supplementary 
Table 4). However, the addition of CCT245737 (150mg/
kg p.o.) significantly increased the antitumor activity 
Figure 4: Development and validation of a pharmacodynamic biomarker assay for CCT245737 activity in human lung 
tumor xenografts. A. Enhanced activity of gemcitabine and carboplatin combined with CCT245737 compared with either CCT245737 
alone (150mg/kg p.o.) or gemcitabine and carboplatin without CCT245737 (100mg/kg i.v. and 5mg/kg i.p., respectively) in Calu6 human 
lung cancer xenografts. Values are mean±SE, n = 6-8 mice per point. The black arrows indicate the time of gemcitabine and carboplatin drug 
administration, the gray arrow when gemcitabine was administered and the open arrow heads the time of CCT245737 administration. B. 
Western blot of biomarker expression in Calu6 tumor xenografts treated as in A.. Samples were taken 6h after the last dose of CCT245737 
from individual mice and analysed by western blotting as described in Materials and Methods with GAPDH as a loading control. C. 
Expression of pS296 CHK1 and D. total CHK1 expression measured in the same human tumor xenograft samples as shown in B. using 
novel ELISA methods the development of which are described in Methods and Materials and Results.
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of gemcitabine giving a growth delay of 19.3±1.7 days 
(mean±SD, P < 0.001, Supplementary Table 4). This 
enhancement was associated with no body weight loss in 
drug treated animals (Supplementary Figure 5A). Figure 
3B and Supplementary Table 4 show the effect of different 
doses of CCT245737 up to a maximum of 150mg/kg p.o. 
on the antitumor effects of a fixed dose of gemcitabine 
(100mg/kg i.v.) in HT29 xenografts. As expected there 
appears to be a saturable effect of CCT245737 dose on 
antitumor activity with the greatest effect occurring 
at around 100mg/kg p.o. At doses up to 50mg/kg p.o. 
CCT245737 there was a steep increase in the effects of 
this CHK1 inhibitor on the tumor growth delay response to 
gemcitabine indicating that low doses of CCT245737 may 
still have marked therapeutic activity in this combination. 
These treatments were minimally toxic with a body 
weight nadir on day 16 and only 2.5% weight loss in the 
combination arm (Supplementary Figures 5B & 5C). In 
addition, there was no antitumor effect of CCT245737 
alone at the combination maximum tolerated dose (MTD, 
150mg/kg p.o.) and only a small increase in antitumor 
activity of gemcitabine alone at the MTD of 200mg/
kg i.v. from 3 to 6 days (Figure 3B and Supplementary 
Table 4). Importantly, these results clearly show that the 
combination of CCT245737 with gemcitabine can readily 
achieve much greater antitumor activity than either agent 
alone at their respective MTDs. Moreover there was no 
increase in toxicity thus validating the therapeutic utility 
of CHK1 inhibitors in vivo.
These antitumor studies with CCT245737 were 
extended into combinations employing other anticancer 
drugs such as irinotecan in the colon cancer HT29 
xenograft model (Figure 3C, Supplementary Table 5). 
Once again there was no antitumor activity of CCT245737 
alone at the combination MTD (1.0±1.0 days growth delay, 
mean±SD), however, irinotecan had substantial antitumor 
activity alone at the dose employed with a growth delay 
of 6.2±4.6 days (mean±SD, n = 6). Nevertheless the 
addition of CCT245737 doubled the growth delay induced 
by irinotecan to 12.4 days (P < 0.05) with a body weight 
nadir on day 10 of only 2% loss (Supplementary Figure 
5D). Studies in SW620 colon cancer xenografts (Figure 
3D) showed that CCT245737 and gemcitabine were 
minimally active as single agents and the combination 
showed a significantly enhanced antitumor activity 
compared with gemcitabine alone (7.3±2.1 versus1.5±2.3 
days growth delay, P < 0.001, Supplementary Table 5) 
with minimal toxicity (4.3% body weight loss on day 9, 
Supplementary Figure 5E). These results demonstrate 
that CCT245737 can significantly enhance the antitumor 
activity of irinotecan and gemcitabine in a number of 
different human tumor xenograft models. Furthermore, 
when tested in HT29 tumors, the activity of gemcitabine 
combined with CCT245737 was greater than could be 
achieved at the MTD of either agent alone. 
A novel, quantitative and sensitive biomarker 
assay for CHK1 activity
CCT245737 may be evaluated in several clinical 
settings, including solid tumors treated with genotoxic 
drugs, such as lung cancers. This will require a validated 
assay for a suitable PD biomarker to confirm that CHK1 
inhibition has occurred. We therefore developed an ELISA 
for measuring S296 CHK1 autophosphorylation (pS296) 
in human tumor material as this is the most sensitive and 
specific proximal biomarker of CHK1 kinase activity 
(see Materials and Methods for details). Figure 4A shows 
that CCT245737 alone or gemcitabine plus carboplatin 
combined (a standard treatment for lung cancer) had 
minimal antitumor activity in the Calu6 RAS mutant 
NSCLC human tumor xenograft model (Supplementary 
Table 5). The addition of CCT245737 to the genotoxic 
agents resulted in a statistically significant 9 day increase 
in tumor growth delay (Supplementary Table 5, P < 
0.001) with minimal weight loss (nadir on day 3 = 2%, 
Supplementary Figure 5F). Western blotting for PD 
Table 1: Summary of in vitro MIA, SRB & PI data for CCT245737
Cells MIA(µM)
GI50
(µM)
Genotoxic
Agent
Combination GI50
(µM)
Potentiation Index
(PI)
HT29 0.030±0.012   (n = 6) 0.70±0.29  (n = 6) SN38 0.39±0.061        (n = 3) 1.8±0.31*    (n = 3)
Gem 0.09±0.023        (n = 6) 7.9±2.1***   (n = 6)
SW620 0.22±0.047     (n = 3) 5.4±1.4      (n = 5) SN38 1.8±0.57            (n = 4) 3.1±1.5*       (n = 4)
Gem 0.33±0.064        (n = 7) 17±3.4***     (n = 7)
MiaPaCa-2 0.063±0.011   (n = 3) 1.3±0.40     (n = 3) SN38 0.43±0.062        (n = 3) 3.1±0.43*     (n = 3)
Gem 0.066±0.025      (n = 3) 23±9.6         (n = 3)
Calu6 0.084±0.0070 (n = 3) 0.41±0.059 (n = 3) SN38 0.32±0.021        (n = 3) 1.3±0.084*   (n = 3)
Gem 0.046±0.0069    (n = 3) 9.1±1.5*       (n = 3)
Mitosis induction assay (MIA IC50) results and cytotoxicity (GI50) values were determined as described in Material and 
Methods.  Potentiation index (PI) is the ratio of GI50 / Combination GI50.  Potentiation index (PI) values.1 indicate potentiation 
of the genotoxic drug. Values are mean±SD of n independent determinations. Statistical significance: *, P < 0.05; **, P < 
0.01; ***, P < 0.001. 
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biomarker changes in Calu6 xenograft tumors taken from 
individual mice (Figure 4B) showed that the combination 
of gemcitabine and carboplatin markedly induced pS296 
CHK1 but had minimal effects on pS317 and pS345 
CHK1 signals, consistent with our previous studies (Figure 
1D [24, 28]). The addition of CCT245737 completely 
abolished the pS296 signal but actually enhanced both 
pS317 and pS345 CHK1 levels - confirming once again 
that pS296CHK1 is a sensitive, robust and reproducible 
biomarker of CHK1 inhibition. There were minimal 
changes in total CHK1 expression. Using the same Calu6 
tumor lysates from these studies we show that the ELISA 
assay for pS296 CHK1 accurately reproduced this signal 
as detected by western blotting (Figure 4C). In addition 
the ELISA for total CHK1 showed minimal changes 
consistent with the immunoblotting results (Figure 4D). 
Both assays were capable of detecting recombinant 
pS296 and total CHK1 down to a concentration of 0.4nM 
(assuming a signal:noise ratio of 2:1). These results show 
that we have developed an accurate and sensitive ELISA 
for pS296 CHK1, a biomarker of CHK1 activity, which 
can be quantified in human tumor tissue.
Single-agent antitumor activity of CCT245737 
in an Eµ-Myc driven mouse model of B-cell 
lymphoma
The deregulation of certain oncogenes such as 
MYCN in neuroblastoma and C-MYC in lymphoma 
appears to be associated with an increase in single-agent 
CHK1 sensitivity, possibly through enhanced replication 
Figure 5: Antitumor activity of single-agent CCT245737 in an Eµ-Myc mouse model of human B-cell lymphocytic 
leukemia. A. Effect of CCT245737 treatment on: inguinal (Ing), brachial/axillary (Brac/Ax) and mesenteric (Mes) lymph node (LN) 
mass compared with controls in Eµ-Myc tumor transplanted mice. These sites are commonly associated with infiltrating B-cell lymphoma 
in this model system. B. Effect of CCT245737 treatment on normal lung tissue mass and C. bone marrow cell number in Eµ-Myc tumor 
transplanted mice. D. Effect of CCT245737 treatment on mouse body weight. Animals were administered CCT245737 (150mg/kg p.o.) 
or vehicle, once daily for 9 days (as indicated by arrows) starting 10 days post-implantation. Mice were culled 24h after the last treatment. 
Values are mean±SD, n = 7-9 and statistical analysis was by Students t-test: *P < 0.05 indicates a significant difference from vehicle control 
treated animals.
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stress. We therefore evaluated the antitumor activity 
of CCT245737 in an Eµ-Myc driven transgenic mouse 
transplant model of B-cell lymphoma that infiltrates the 
lymph glands. Figure 5A clearly shows that 9 days oral 
administration of 150mg/kg CCT245737 significantly 
reduced the weight of the inguinal, brachial/axillary and 
mesenteric lymph nodes compared with vehicle treated 
control animals (P < 0.05). Moreover there were minimal 
effects on normal tissues such as the lung (Figure 5B, p = 
0.904) and bone marrow (Figure 5C, p = 0.0838) or kidney 
(p = 0.959, not shown). There was a significant decrease 
in thymus weight following CCT245737 treatment (p < 
0.01) suggesting some tumor involvement and spleen 
weight was increased significantly (p < 0.01) suggesting 
some splenomegaly (not shown). The treatment was well 
tolerated as evidenced by stable body weights (Figure 5D) 
and negligible effects on other parameters such as water 
consumption and body temperature (data not shown). 
Consequently these results show that CCT245737 has 
significant antitumor activity as an oral single-agent in a 
Myc-driven mouse model of B-cell lymphoma. 
DISCUSSION
CCT245737 is a novel, potent, selective and well-
tolerated orally active CHK1 inhibitor, and our clinical 
development candidate. Enzyme kinetic and modeling 
data clearly show that CCT245737 is a potent, ATP-
competitive inhibitor of human CHK1 kinase with an 
IC50 of 1.4nM. Initial screening against other kinases 
demonstrated an appropriate selectivity profile with 
subsequent studies showing ≥ 500-fold selectivity for 
all but five kinases. Importantly there was minimal 
inhibition of CHK2 which has little therapeutic utility in 
genotoxic combinations [29, 30]. There was also no cross-
reactivity with CDK1 and 2, inhibition of which might 
antagonize the cytotoxic effects of CHK1 inhibition, as 
CDK1 activation has been implicated in CHK1 inhibitor-
based cell killing [30]. This selectivity profile compares 
favorably with other CHK1 inhibitors, such as AZD7762 
[31], GDC-0575 [32], PF00477736 [33] and LY2603618 
[34]. There was evidence of potent intracellular CHK1 
inhibition in several human tumor cell lines following 
genotoxic stress (Table 1) and this was associated with 
abrogation of a late S, G2/M checkpoint (Figure 1C) 
consistent with CHK1 inhibition and similar to other 
CHK1 inhibitors [28, 33] . Several previous studies have 
established that certain classes of genotoxic anticancer 
drugs are potentiated more effectively than others by 
CHK1 inhibitors e.g. antimetabolites and topoisomerase 
1 inhibitors [25, 35]. 
Using a rapid and sensitive assay for determining 
the combination GI50 (where a fixed concentration of the 
genotoxic agent is combined with a range of CCT245737 
concentrations) we derived a potentiation index (ratio of 
IC50 for CCT245737 alone: combination GI50) and showed 
that the cytotoxicity of both gemcitabine and SN38 were 
significantly enhanced (Table 1). This technique was 
validated by comparison with the more conventional 
approach where a non-toxic concentration of a CHK1 
inhibitor is combined with increasing concentrations 
of the genotoxic drug (Supplementary Figure 3) with 
qualitatively similar results. The rapid technique presented 
here has the advantage of quickly establishing a genotoxic 
GI50 in contrast to the most active non-toxic CHK1 
inhibitor concentration. Moreover, this rapid technique 
was more sensitive than the conventional approach with 
2 to 3-fold greater PI values, allowing evaluation and 
ranking of relatively non-potent and selective compounds 
in the early stages of the CHK1 inhibitor drug discovery 
project.
It is clear from these and other available data that 
antimetabolites such as gemcitabine are potentiated 
by several CHK1 inhibitors to a greater extent than 
topoisomerase 1 inhibitors [24, 25, 35]. This may reflect 
a greater ability of the former to deplete nucleotide pools 
and enhance replication stress with an increased reliance 
on CHK1 to avoid replication fork collapse [36, 37]. 
Our cellular PD biomarker studies reproducibly showed 
that there was a concentration-dependent inhibition of 
genotoxic induced pS296 CHK1 autophosphorylation 
by CCT245737. Moreover this pS296 CHK1 signal was 
a more sensitive and robust readout of CHK1 inhibition 
in our systems than other phospho-CHK1 sites. This is in 
contrast to other reports [38], possibly due to the fact that 
pS296 is a specific and direct readout of CHK1 activity 
[39], an essential requirement for PD biomarkers of kinase 
inhibitors. This CCT245737 concentration-dependent 
loss of pS296 CHK1 signal was coincident with loss of 
cell cycle arrest, increased DNA damage and apoptosis 
implying that CHK1 inhibition induced cell death [3, 40].
Pharmacokinetic studies with CCT245737 showed 
complete oral bioavailability with linear pharmacokinetics 
and high tumor/plasma ratios consistent with extensive 
tumor exposure. Pharmacodynamic studies showed that 
CCT245737 concentrations required for inhibition of 
gemcitabine-induced pS296 CHK1 and pY15 CDK1 were 
readily achieved in tumors at 24h following a single oral 
dose of 50mg/kg (Figure 2C). We and others have shown 
that an effective antitumor combination strategy involves 
delaying CHK1 inhibitor administration by 24h following 
a genotoxic drug dose and then extending effective CHK1 
exposure for a further 48h [7, 24, 35]. Moreover there 
were no detectable pharmacokinetic interactions with 
this CHK1 inhibitor chemical class and the genotoxic 
agents studied. The PK-PD relationship described here for 
CCT245737 and its high oral bioavailability, make this an 
ideal compound for clinical evaluation. `
Efficacy studies in a number of different xenograft 
tumor models showed that CCT245737 enhanced the 
activity of both gemcitabine and irinotecan. Importantly 
and uniquely, we show for the first time that a CHK1 
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inhibitor can markedly enhance the antitumor activity of 
gemcitabine to a greater extent than can be achieved by the 
MTD of either agent alone. Moreover the dose-response 
curve had a relatively steep initial phase, suggesting 
that a therapeutically useful increase in gemcitabine 
activity is feasible at modest doses of CCT245737, as 
might be achieved in early stage clinical trials. This 
response appeared to plateau at doses above 50mg/kg, 
implying that very high concentrations of CCT245737 
may not be required for optimal therapeutic activity and 
consistent with the idea that CHK1 inhibition in tumors 
may enhance DNA damage or stalled replication fork 
collapse [8, 13]. These observations further support the 
clinical development and evaluation of CCT245737 in 
combination with genotoxic agents such as gemcitabine. 
To this end we have shown that CCT245737 can 
significantly enhance the antitumor activity of both 
gemcitabine and carboplatin in a RAS mutant NSCLC 
human tumor xenograft model. This is an area of unmet 
clinical need and a disease setting in which clinical 
testing of CCT245737 is proposed. In order to ensure that 
these antitumor effects are a result of CHK1 inhibition 
we also carried out PD studies and showed once again 
that pS296 CHK1 inhibition is a more sensitive, robust 
and reproducible marker of CHK1 inhibition than either 
pS317 or pS345 CHK1. Indeed, induction/inhibition of 
pS317 and pS345 CHK1 by CCT245737 appeared to be 
either concentration and/or time dependent (Figure 1D 
and Supplementary Figure 3) as well as context dependent 
(Figure 2C and 4B) possibly through differences in 
feedback repression of ATR/ATM, DNA damage and 
repair capacity or PP2A and WIP1 phosphatase activity. 
Consequently we developed a novel, sensitive and 
quantitative ELISA for pS296 CHK1 which will facilitate 
the clinical evaluation of this combination and allow 
target inhibition monitoring in the patient. Nevertheless 
other indirect readouts such as CDC25A or pY15 CDK1 
loss, apoptosis markers and γH2AX and RAD51 foci 
formation may prove useful in confirming that functionally 
significant CHK1 inhibition has occurred [8, 24, 41, 42]. 
An intriguing aspect of CHK1 inhibitor development 
is the realization that these compounds may exhibit single-
agent activity in particular malignancies. It appears that 
tumors with deregulated MYC expression or high levels of 
replication stress are very sensitive to single-agent CHK1 
inhibition [17, 18, 21, 22]. To expand the potential clinical 
utility of CCT245737 monotherapy we have shown that 
it has significant antitumor activity in an Eµ-Myc driven 
transgenic murine model of infiltrating B-cell lymphoma 
(Burkitt’s-type lymphoma) [43]. MYC gene alterations 
are common in other B-cell neoplasms and are often 
associated with poor outcomes [44]. CCT245737 as a 
single-agent was well tolerated in the Eµ-Myc transgenic 
model and had minimal effects on normal tissues such as 
lung and bone marrow and kidney, although there was 
some evidence of splenomegaly. However the use of 
an isogenic MYC inducible model would be even more 
definitive. Nevertheless, these results are consistent with 
studies using the CHK1 inhibitor PF-0477736 in a variety 
of Eµ-Myc driven transgenic murine lymphoma cell lines 
[18] and are directly comparable with antitumor studies 
using UCN01 (5mg/kg x 9 days), a non-selective CHK1 
inhibitor in the same model [45]. In the latter case clear 
evidence of tumor growth inhibition was associated with 
a decreased blood cell count, possibly due to off-target 
effects of UCN01 and in marked contrast to this study. 
Should CHK1 inhibitors prove successful in the clinic it 
will be important to identify biomarkers of sensitivity to 
facilitate patient selection and to establish other molecular 
targets, which upon inhibition give a synthetically lethal 
phenotype [46].
In conclusion, we have investigated the preclinical 
pharmacology, PK-PD relationships and antitumor 
activity of the novel, potent, selective and orally active 
CHK1 clinical development candidate CCT245737. We 
clearly show that CCT245737 enhanced the antitumor 
activity of several anticancer agents in vivo and uniquely 
demonstrate that for gemcitabine this was greater than 
the activity achievable by dose escalation of either agent 
alone. The lack of additional toxicity in the combinations 
thus provides a valuable therapeutic gain. We also show 
that pS296 CHK1 is a robust PD biomarker of CHK1 
activity and provide a novel, quantitative ELISA-based 
assay suitable for the measurement of this biomarker in 
clinical material. We demonstrate that CCT245737 has 
single-agent antitumor activity in a Myc driven model 
of B-cell lymphoma, providing preclinical evidence of a 
potential adult clinical monotherapy setting. Consequently 
CCT245737 is in late stage preclinical development in 
preparation for a first-in-man phase I clinical trial. 
MATERIALS AND METHODS
Drugs and compounds
CCT245737 (Figure 1A) and its S-enantiomer 
CCT252463 were synthesized as described [47]. 
Irinotecan was purchased from Pfizer and its active 
metabolite (SN38) from LKT laboratories. Gemcitabine 
was obtained from Eli Lilly. All other compounds were 
purchased from Sigma.
Human tumor cell lines
The colon tumor cell lines HT29 (p53-/-, APC+/-, 
PIK3CA+/-, BRAF+/- and SMAD4-/-) and SW620 (p53-/-, 
KRAS-/-, APC-/-, SMAD4-/- and MAP2K4-/-), the pancreatic 
cancer cell line MiaPaCa-2 (p53-/-, KRAS+/-, KDM6A-/-, 
CDKN2a; p14-/- and CDKN2A) and the non-small cell 
lung cancer Calu6 cell line (p53-/- and KRAS+/-) were 
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purchased from ATCC (Lot numbers 4487729, 3924081, 
57866607 and 58683029, respectively and Sanger Centre 
data http://www.sanger.ac.uk/genetics/CGP/cosmic). 
Cells were grown in Dulbecco’s modified Eagles medium 
containing 10% fetal calf serum and 2mM glutamine and 
were mycoplasma free [24]. 
In vitro kinase assays
Commercial in vitro 33P radiometric kinase assays 
were carried out against 124 human kinases using 10µM 
CCT245737 at ATP concentrations corresponding to the 
kinase Km,ATP (MRC Phosphorylation Unit, Dundee). 
Other kinase IC50 determinations for CHK2 and FLT3 
were performed using a commercial assay (Z’-Lyte, 
Invitrogen) or in-house with recombinant human CHK1 
on a LabChip® EZ Reader II (PerkinElmer) or CDK1 in a 
DELFIA assay (PerkinElmer). 
Cellular cytotoxicity, G2 checkpoint abrogation 
and potentiation assays
Assays were performed as described [24]. 
Cytotoxicity was determined as the drug concentration 
that gave 50% inhibition of tumor cell proliferation (GI50) 
using a 96h (i.e. 4-doublings) Sulforhodamine B (SRB) 
assay. Inhibition of intracellular CHK1 activity was 
measured using a cell based ELISA for the abrogation of 
an etoposide induced G2 checkpoint (mitosis induction 
assay, MIA [24]). The IC50 for G2 checkpoint abrogation 
(MIA) was determined in the presence of nocodazole 
using UCN01 as a positive control. The activity index 
(AI) was used as a measure of the compounds ability to 
induce mitosis relative to its toxicity (i.e., ratio of MIA 
IC50: 96h SRB GI50). Routine potentiation studies were 
carried out using a fixed concentration (GI50) of either 
gemcitabine or SN38 in combination with a range of 
CCT245737 concentrations to determine the combination 
GI50 of CCT245737. The ability of CCT245737 to 
enhance gemcitabine or SN38 cell killing was expressed 
as a potentiation index (PI) equal to the ratio of the 
GI50 for CCT245737 alone versus the combination GI50 
for CCT245737 (see above). PI values > 1 indicate 
potentiation of the genotoxic activity. In addition, a 
series of experiments was carried out using fixed, non- 
or minimally toxic concentrations of CCT245737 
(≤GI20) with a range of different concentrations of 
gemcitabine or SN38 to determine the extent to which 
CCT245737 enhanced drug cytotoxicity compared with 
the genotoxic agent alone, i.e. conventional PI (ratio GI50 
genotoxic alone: GI50 genotoxic combined with non-toxic 
CCT245737 concentration, Con PI).
Immunoassays
Western blotting was carried out as described 
[24]. ELISA assays for pS296 CHK1 and total CHK1 
were developed and validated for use in vitro and in 
tumor homogenates. Tumor samples for ELISA and 
western blotting were lysed in CHAPS buffer (1% 
CHAPS in 150mM NaCl, 50mM Tris-HCl pH 8.0, 1mM 
EDTA, 0.2mM PMSF and 1:50 Sigma Phosphatase 
inhibitors 2 and 3 and 1:100 Sigma protease cocktail) 
and immunoblotted. ELISA assays were based on 
commercially available kits with modifications (Cell 
Signalling Technologies). For pS296 CHK1 detection the 
commercial pS317 CHK1 antibody was replaced with 
a pS296 CHK1 antibody (Cell Signalling Technology). 
Xenograft tumor homogenate was added in duplicate 
to 96 well plates (100µl containing 40ug protein) and 
quantification of the colorimetric readout was determined 
at 450nm using a PerkinElmer 2103 EnVision Multilabel 
plate reader. 
Cell cycle analysis
Cell cycle analysis using propidium iodide and 
bromodeoxyuridine staining was as described [28].
Animal studies
Compound tolerability and pharmacokinetic 
investigations were carried out in female BALB/c mice 
(Charles River). Human tumor xenografts were established 
s.c. in female CRTac:Ncr-Fox1(nu) athymic mice and 
treated as previously described [24, 28]. The vehicle for 
oral administration of CCT245737 was DPTW (10% 
DMSO, 20% PEG400, 5% Tween 80 and 65% water) and 
gemcitabine and irinotecan were administered in their 
respective clinical vehicles. Treatments were generally 
initiated when tumors reached a mean diameter of 5-6mm 
(day 0). For combination studies, CCT245737 was given 
orally 24 and 48h after genotoxic drug administration, 
previously determined as an optimal schedule for CHK1 
inhibitor and genotoxic drug combinations [24]. In 
HT29 xenograft studies, gemcitabine was administered 
at 100mg/kg i.v. on days 0,7 and 14 and CCT245737 at 
the indicated doses on days 1,2,8,9,15 and16. Irinotecan 
was administered at 25mg/kg i.p. on days 0,4 and 8 with 
CCT245737 administered at 150mg/kg p.o. on days 
1,2,5,6,9 and 10. In SW620 and Calu6 xenograft studies, 
gemcitabine was administered at 100mg/kg i.v. on days 0,4 
and 8 and CCT245737 subsequently at 150mg/kg on days 
1,2,5,6,9 and 10. For the Calu6 xenograft studies involving 
gemcitabine and carboplatin, drugs were administered 
at 100mg/kg i.v. and 5mg/kg i.p., respectively on day 0 
with gemcitabine alone at 100mg/kg i.v. on day 7 with 
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CCT245737 at 150mg/kg p.o. on days 1,2,8 and 9. The 
genotoxic drug doses employed were sub-maximally 
active to facilitate detection of subsequent potentiation. 
Initial treatment groups contained from 6 to 10 mice and 
animals were inspected daily and tumor size and volume 
measured every 2 or 3 days. Tumor volume and growth 
delay were determined as previously described [28]. 
Transgenic Eµ-Myc mice which develop aggressive 
infiltrating lymphoma were established and monitored 
as previously described [48, 49]. To generate transgenic 
Eµ-Myc driven lymphoma allografts, tumor cells from 3 
separate tumors were harvested, cells counted and injected 
via a tail vein. Six mice were set up per tumor to provide 
3 control and 3 treated animals, giving a maximum of 
9 mice per treatment group. Animals were monitored 
daily and continuously using RFID transponders to 
measure temperature, activity and water consumption 
as previously described [49]. For studies of single-agent 
CCT245737 activity in mice injected with transgenic Eµ-
Myc lymphoid tumor cells, CCT245737 was administered 
at 150mg/kg p.o. for 9 successive days with culling 24h 
after the last dose. Lymph nodes and other tissues were 
removed from vehicle and CCT245737 treated mice and 
their weights and tissue/body weight ratios compared to 
assess antitumor activity. Bone marrow cellularity was 
also determined to check for tumor cell involvement. All 
mice were handled in compliance with local and national 
animal welfare guidelines [50].
Pharmacokinetics
Compounds were extracted from whole blood, 
plasma and tissue homogenates with methanol-
containing internal standards using established protocols. 
Drug concentrations were determined using liquid 
chromatography/tandem mass spectrometry (LC/MS-MS) 
and pharmacokinetics were calculated using Pharsight 
WinNonLin software (version 5.2.1) as previously 
described [28]. 
Statistics
Statistical significance (*, P < 0.05; **, P < 0.01; 
***, P < 0.001) was determined using an unpaired, one-
tailed or two-tailed t-test or one-way ANOVA with either 
Tukey or Dunnett test, as appropriate using GraphPad 
Prism 5 software. 
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